Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anetumab ravtansine - Bayer HealthCare

Next Previous
Drug Profile

Anetumab ravtansine - Bayer HealthCare

Alternative Names: Anti-mesothelin antibody-drug conjugate BAY 94-9343; Anti-mesothelin-ADC-BAY-94-9343; BAY-94-9343; BAY-94-9343-SPDB-DM4

Latest Information Update: 14 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer HealthCare
  • Developer Bayer HealthCare; ImmunoGen; MorphoSys; National Cancer Institute (USA)
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Tubulin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Fallopian tube cancer; Lung cancer; Malignant thymoma; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours

Most Recent Events

  • 12 Feb 2024 ImmunoGen has been acquired by AbbVie
  • 04 Aug 2023 Discontinued - Phase-I for Fallopian tube cancer (Combination therapy, Late-stage disease, Metastatic disease, Recurrent) in Moldova, Belgium, USA, Spain (IV) (Bayer pipeline, August 2023)
  • 04 Aug 2023 Discontinued - Phase-I for Mesothelioma (Combination therapy, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in Italy (IV) (Bayer pipeline, August 2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top